Antibody neutralization of VEGF (bevacizumab) or treatment with SU5416 (tyrosine kinase receptor inhibitor), and pazopanib (VEGFR inhibitor) enhanced the efficacy of anti-TB drugs by normalizing the vascular structure and reducing hypoxia; these morphological changes facilitated improved anti-TB drug penetration and killing of Mtb in the granuloma (34, 35) (Table 1; Figure 1). The gene discussed is KDR; the disease is tuberculosis.